Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?

Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.

Of the big oncology deals since 2016, there are still plenty that could go either way.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

The group has approval for Amtagvi, but now faces the prospect of a solo launch.

Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.

GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.